The combination regimen showed positive progression-free survival results among patients with HER2-positive breast cancer in the phase 3 HER2CLIMB-02 trial, but overall survival data have yet to mature.
microRNAs have shown potential to be used as biomarkers for diagnosing and treating different types of cancers, though their application in doing so had yet to be determined.
Investigators identified a specific subgroup of patients with mantle cell lymphoma who were at higher risk by defining a combination of MIPI, Ki-67, and p53/TP53 alternations.